JENNIFER MULLINS: Open Payments
NPI 1174063234 · ERLANGER, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$736 in 30 payments from 11 companies in 2025. Trend: 2023 $1,649 · 2024 $1,310 · 2025 $736
Food & beverage: $736
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $136 |
| Teva Pharmaceuticals USA, Inc. | 6 | $120 |
| Axsome Therapeutics, Inc. | 2 | $118 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $84 |
| Noven Therapeutics, LLC | 3 | $63 |
| Luye Pharma (USA) Ltd. | 2 | $44 |
| Indivior Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Neurocrine BioSciences, Inc. | 1 | $18 |
Products named: VRAYLAR, Auvelity, AUSTEDO XR, CAPLYTA, ABILIFY MAINTENA, ERZOFRI EXTENDED-RELEASE, Secuado, SUBLOCADE.
Industry payments across KY — which companies pay providers there.
